8-K: Imunon Appoints Kimberly Graper as Interim Chief Financial Officer Following Leadership Transition

Imunon, Inc. announced the termination of its consulting agreement with Monomoy Advisors, LLC and David Gaieros as interim CFO, simultaneously appointing Kimberly Graper, previously VP of Finance, as the new interim Chief Financial Officer.

Summary

• Imunon, Inc. terminated its consulting agreement with Monomoy Advisors, LLC and David Gaieros, who served as the company's interim Chief Financial Officer since June 2024, effective June 13, 2025.
• Kimberly Graper has been appointed as the company's interim Chief Financial Officer, principal financial officer, and principal accounting officer, effective June 13, 2025.
• Ms. Graper joined Imunon in October 2022 as Vice President of Finance and Corporate Controller.
• Her prior experience includes roles as Senior Director and Corporate Controller at F2G Inc., Corporate Controller at Timber Pharmaceuticals, Inc., U.S. Corporate Controller at Anticimex Inc., and Director of Finance and U.S. Controller at Derma Sciences.
• Ms. Graper holds a Bachelor of Science in Accounting from Clemson University and a Juris Doctor from Seton Hall School of Law, and is a Certified Public Accountant in New Jersey.
• Her current compensation includes an annual salary of $244,800 and eligibility for a target annual performance bonus of 30% of her base salary.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The appointment of an internal, highly qualified, and experienced individual to a key financial leadership role suggests stability and continuity, which is generally viewed favorably. There are no negative financial implications or significant disruptions indicated.

Positives

• The appointment of Kimberly Graper, an internal candidate who has been with Imunon since October 2022 as VP of Finance and Corporate Controller, provides continuity and familiarity with the company's financial operations.
• Ms. Graper brings extensive experience in financial reporting, budgeting, SEC compliance, and corporate accounting from various biotech, medical device, and high-growth companies, including her CPA and JD qualifications.

Negatives

• The termination of the previous interim CFO and consulting firm, while a planned transition, represents a change in leadership that could entail a brief period of adjustment.

Future Outlook

The document primarily details a management change and does not provide specific forward-looking statements regarding the company's financial performance or strategic direction, beyond the ongoing role of Ms. Graper as interim CFO.

Industry Context

Changes in executive leadership, particularly in finance roles, are common occurrences in the biotech and pharmaceutical industries. The appointment of an experienced financial professional with a background in clinical-stage biotech and medical device companies aligns with typical industry requirements for financial oversight and SEC compliance.

Comparison to Industry Standards

• The compensation structure for Ms. Graper, including a base salary and performance bonus, is standard for executive roles within the biotech industry.
• Ms. Graper's extensive background in financial reporting and corporate control within the biotech and medical device sectors, including her CPA and JD qualifications, aligns with the high standards expected for a principal financial officer in a publicly traded company.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of an experienced internal candidate to a key financial role may instill confidence in the company's financial management and reporting.
• Employees: The transition of an existing employee into a senior leadership position can foster a sense of internal growth opportunities and stability within the organization.

Next Steps

• Kimberly Graper will continue to serve as the company's interim Chief Financial Officer, principal financial officer, and principal accounting officer.

Key Dates

Recommendation

Keywords

Imunon, IMNN, Chief Financial Officer, CFO, executive appointment, management change, corporate governance, biotech, pharmaceutical, SEC filing, 8-K